MYGN
Myriad Genetics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$3.19
−1.24%Jul 30, 2026, 20:05 UTC
Myriad Genetics reported its second quarter 2026 financial results, with revenue of $190.7 million decreasing 11% year-over-year.
Jul 21, 2026, 13:05 UTC
Myriad Genetics launched FirstGene Multiple Prenatal Screen, a lab test that runs four prenatal genetic screens simultaneously as early as eight weeks.
Source:Jul 10, 2026, 10:45 UTC
Parklands Care Homes has been acquired by Myriad Group, the Essex-based owner of Caring Homes.
Source:Jun 23, 2026, 13:05 UTC
Myriad Genetics expands availability of Precise MRD test for colorectal, renal and breast cancers, supported by a new publication of the MONITOR-Breast study.
Source:Jun 23, 2026, 00:00 UTC
Daniel M. Skovronsky resigned from the Board of Directors of Myriad Genetics Inc, effective June 17, 2026.
Jun 23, 2026, 00:00 UTC
Daniel M. Skovronsky, M.D., Ph.D. was appointed to the Board of Directors of Illumina, Inc. effective June 16, 2026.
Jun 4, 2026, 00:00 UTC
Myriad Genetics Inc. elected Paul M. Bisaro, Rashmi Kumar, and Lee N. Newcomer as Class III directors, effective June 4, 2026.
Jun 2, 2026, 13:05 UTC
Myriad Genetics appointed Raj Jampa as chief technology officer, effective June 1, 2026.
Source: